A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
Standard
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. / Peters, O; Lorenz, D; Fesche, A; Schmidtke, K; Hüll, M; Perneczky, R; Rüther, E; Möller, H-J; Jessen, F; Maier, W; Kornhuber, J; Jahn, Holger; Luckhaus, C; Gertz, H-J; Schröder, J; Pantel, J; Teipel, S; Wellek, S; Frölich, L; Heuser, I.
in: J NUTR HEALTH AGING, Jahrgang 16, Nr. 6, 6, 2012, S. 544-548.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
AU - Peters, O
AU - Lorenz, D
AU - Fesche, A
AU - Schmidtke, K
AU - Hüll, M
AU - Perneczky, R
AU - Rüther, E
AU - Möller, H-J
AU - Jessen, F
AU - Maier, W
AU - Kornhuber, J
AU - Jahn, Holger
AU - Luckhaus, C
AU - Gertz, H-J
AU - Schröder, J
AU - Pantel, J
AU - Teipel, S
AU - Wellek, S
AU - Frölich, L
AU - Heuser, I
PY - 2012
Y1 - 2012
N2 - Mild cognitive impairment (MCI) is etiologically heterogeneous, and a substantial proportion of MCI subjects will develop different dementia disorders. One subtype of this syndrome, amnestic MCI, occurs preferentially but not exclusively in prodromal AD and is characterized by defined deficits of episodic memory.
AB - Mild cognitive impairment (MCI) is etiologically heterogeneous, and a substantial proportion of MCI subjects will develop different dementia disorders. One subtype of this syndrome, amnestic MCI, occurs preferentially but not exclusively in prodromal AD and is characterized by defined deficits of episodic memory.
KW - Germany
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Psychiatric Status Rating Scales
KW - Cohort Studies
KW - Disease Progression
KW - Double-Blind Method
KW - Alzheimer Disease/physiopathology
KW - Amnesia/etiology/prevention & control
KW - Cholinesterase Inhibitors/adverse effects/therapeutic use
KW - Cognition/drug effects
KW - Dementia/prevention & control
KW - Drug Therapy, Combination/adverse effects
KW - Early Termination of Clinical Trials
KW - Galantamine/adverse effects/therapeutic use
KW - Memantine/adverse effects/therapeutic use
KW - Mild Cognitive Impairment/drug therapy/etiology/physiopathology
KW - Nootropic Agents/adverse effects/therapeutic use
KW - Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
KW - Germany
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Psychiatric Status Rating Scales
KW - Cohort Studies
KW - Disease Progression
KW - Double-Blind Method
KW - Alzheimer Disease/physiopathology
KW - Amnesia/etiology/prevention & control
KW - Cholinesterase Inhibitors/adverse effects/therapeutic use
KW - Cognition/drug effects
KW - Dementia/prevention & control
KW - Drug Therapy, Combination/adverse effects
KW - Early Termination of Clinical Trials
KW - Galantamine/adverse effects/therapeutic use
KW - Memantine/adverse effects/therapeutic use
KW - Mild Cognitive Impairment/drug therapy/etiology/physiopathology
KW - Nootropic Agents/adverse effects/therapeutic use
KW - Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
M3 - SCORING: Journal article
VL - 16
SP - 544
EP - 548
JO - J NUTR HEALTH AGING
JF - J NUTR HEALTH AGING
SN - 1279-7707
IS - 6
M1 - 6
ER -